Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza Key Highlights · POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines · POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo · Trial results demonstrate expected utility in severe influenza […]